Analysis of the Efficacy and Pharmacological Mechanisms of Action of Zhenren Yangzang Decoction on Ulcerative Colitis Using Meta-Analysis and Network Pharmacology

Table 3

Main outcomes in the included RCTs.

Study year [ref]	Main outcomes	Main results (effect size)	Adverse events
Yuan JY, 2009 [11]	(1) Clinical efficacy		No adverse reactions
	Total effective rate	OR, 3.32 [0.63, 17.43]
	Recovery rate	OR, 3.10 [1.24, 7.79]
	Recurrence rate	OR, 0.18 [0.05, 0.61]
Zhao KH, 2010 [12]	(1) Clinical efficacy		n.r.
	Total effective rate	OR, 4.15 [0.39, 44.57]
	Recovery rate	OR, 2.86 [0.72, 11.31]
Wang L, 2015 [27]	(1) Clinical efficacy		n.r.
	Total effective rate	OR, 2.43 [0.81, 7.30]
	Recovery rate	OR, 8.22 [2.16, 31.27]
Han Y, 2019 [28]	(1) Clinical efficacy		Experimental: nausea (n = 3); Control: nausea (n = 3); somnolence (n = 1); vomit (n = 2)
	Total effective rate	OR, 3.95 [0.96, 16.35]
	Recovery rate	OR, 1.97 [0.67, 5.73]
	(2) Syndrome score of TCM
	Total score	MD, −3.45 [−4.30, −2.60]
	Diarrhea score	MD, −0.71 [−0.84, −0.58]
	Abdominal pain score	MD, −0.73 [−0.85, −0.61]
	Mucopurulent bloody stool score	MD, −1.24 [−1.55, −0.93]
	Tenesmus score	MD, −0.77 [−1.03, −0.51]
	(3) Sutherland disease activity indexes	MD, −1.32 [−1.69, −0.95]
	(4) Serum cytokines
	IL-6	MD, −14.14 [−17.50, −10.78]
	IL-8	MD, −48.60 [−52.96, −44.24]
	TNF-α	MD, −27.06 [−31.80, −22.32]
Dai AC 2021 [29]	(1) Syndrome score of TCM		Experimental: nausea (n = 1); Control: nausea (n = 3); somnolence (n = 2); vomit (n = 3)
	Total score	MD, −2.67 [−3.16, −2.18]
	(2) Serum cytokines
	IL-6	MD, −16.96 [−19.89, −14.03]
	TNF-α	MD, −25.52 [−29.76, −21.28]

RCT: randomized controlled trial; TCM: traditional Chinese medicine; IL: interleukin; TNF: tumor necrosis factor; OR: odds ratio; MD: mean difference; n.r.: not reported.